Drug Trial Radar · NCT06606093
Evaluate the Efficacy and Safety of DWP16001 in Type 2 Diabetic Nephropathy with Moderate Renal Impairment Patients
Last checked: Nov 19, 2026Latest source record: Sep 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
348
Planned (sponsor's estimate)
Start
Sep 23, 2024
Primary completion
Sep 1, 2026
Study completion Jan 31, 2027
Sponsor
- Lead sponsor
- Daewoong Pharmaceutical Co. LTD.Industry
- Sponsor type
- Industry
- First posted
- Sep 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the efficacy and safety of DWP16001 in type 2 diabetic nephropathy with moderate renal impairment patients (CKD stage 3)
Conditions
- Type 2 Diabetic Nephropathy
Interventions
DWP16001 PlaceboDrug
1 tablet, Orally, Once daily single dose
DWP16001 0.3mgDrug
1 tablet, Orally, Once daily single dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in HbA1c at Week 24 from Baseline after RandomizationTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Korea university ansan hospital
Ansan, Gyeongggi-do, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.